ABT
The deal arrives with a receipt
Abbott just reminded everyone that big acquisitions don’t come with confetti — they come with math. The company lowered its full-year adjusted earnings outlook to $5.38 to $5.58 per share, down from $5.55 to $5.80, saying the roughly $21 billion Exact Sciences acquisition is pressuring profits.
Sales story stays intact, for now
The odd part? Abbott didn’t flinch on its 2026 comparable sales growth target of 6.5% to 7.5%. So the top-line growth narrative is still standing, but the bottom line is taking the first punch. That’s usually the part Wall Street notices when it’s in a mood.
Why investors care
This is the classic big-deal hangover: you buy the future, but the present gets a little bruised. If you own ABT, the question isn’t whether the cancer-screening play makes strategic sense — it’s how quickly the company can turn a giant check into earnings that don’t look like they’ve been to the gym and skipped leg day.
Big picture: Abbott’s still betting that cancer diagnostics is worth the pain. Investors just got a fresh reminder that “transformational” often means “temporarily expensive.”